Jan Garfinkle , MBA

Director

Arboretum Ventures
Ann Arbor, MI

Jan Garfinkle is a founder and managing director at Arboretum Ventures. Arboretum assists developing medical device, diagnostic, healthcare, and life science start-up companies. Ms. Garfinkle has over 20 years in the medical device and biomedical engineering sectors. At Arboretum, Ms. Garfinkle heads the fundraising efforts in addition to being a member of the Investment Commitee. She led Arboretum's investment in HandyLab also serving on their board of directors before it was acquired by Becton Dickinson. Ms. Garfinkle has led investments in numerous other startups including CardioMEMS, Uptake Medical, BAROnova, Vasonova, Esperion, NXThera, Life Magnetics, Sonitus Medical and Cereve. She is a director of Accord Biosciences, NXThera, Life Magnetics, Sonitus and Cereve, and as a board observer on Uptake Medical and Esperion. Prior to Arboretum, Ms. Garfinkle spent twelve years at two successful start-up medical device companies: Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI), both of which were acquired by Eli Lilly and spun into Guidant Corporation. ACS and DVI revolutionized the cardiovascular market place with the development and FDA approval of some of the earliest angioplasty and atherectomy systems for the treatment of coronary artery disease. ACS was the first medical device company to grow from zero to $100 million in revenue in five years. She joined each company early in their development, and held key management roles in marketing, clinical research and sales at these companies. Ms. Garfinkle was also the President of Strategic Marketing Consultants. MC provided extensive market analysis, regulatory and reimbursement review, business plan development and due diligence to life science start ups, venture funds, and universities. She holds a B.S. in Bioengineering from the University of California-Berkeley and an M.B.A. from The Wharton School of the University of Pennsylvania.